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Imaging of the fatty liver
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S u m m a r y
The global emergence of obesity as an epidemic has made fatty liver disease a public health problem. 
The net consequence of hepatic steatosis is progresses to steatohepatitis and cirrhosis. Although liver 
biopsy is currently the gold standard for diagnosis, there is a need for less invasive methods. Imaging 
by ultrasound, computerized tomography and magnetic resonance are all able to demonstrate liver 
steatosis. In this paper, these imaging techniques are critically assessed.
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Liver steatosis is referred to as the state of liver paren­
chyma when excessive accum ulation of fat takes place 
in hepatocytes. Triacyloglyceroles are usually the major 
compound, bu t sfingolipides, pfospholipides, cholesterol 
and its esters may also occur. In physiologic conditions 
the liver weights about 1600 g in adult males and about 
1400 g in adult females and accounts for 1,8-3,1% body 
weight. The norm al liver contains small droplets of fat 
in hepatocyte cytoplasm; however, they are invisible 
on histologic examination. It is agreed tha t if over 5% of 
hepatocytes exhibits signs of lipid accumulation, the state 
may be referred to as steatosis [1]. The definition is not 
widely accepted however, because some authors maintain 
that liver steatosis should be diagnosed when not less than 
50% of hepatocytes are affected by fat accumulation or lipid 
mass exceeds 5% of the liver weight [2].
Confirmative diagnosis of fatty  liver is primarily based 
on imaging examination, e.g. ustrasonography, computed 
tomography and magnetic resonance. All these imaging 
techniques perm it diagnosis of liver steatosis; however, 
evaluation of lipid content or degree of steatosis is qualitative 
rather, than quantitative. Histopathologic examination is 
rarely used for confirmation of liver steatosis, although in 
view of development of alcoholic hepatitis or NASH, its role 
is very crucial [3]. It is noteworthy that biopsy is an invasive
technique burdened w ith 0.1-0.6% risk of complications 
(bleeding, pneumothorax, biliary peritonitis) and 0.001­
0.003% mortality due to haemoperitoneum [4].
Assessment of liver steatosis in imaging examinations
Ultrasonography (US)
In patients w ith liver steatosis minor or medium enlarge­
ment of the organ is found on ultrasonographic examination 
[5]. Accumulation of lipid compounds results in diffuse 
changes in echogenicity of the liver w ith the presence of 
hyperechoic areas on the US examination which cause 
lim ited imaging of the diaphragm and blood vessels [6]. 
According to Scatarige et al. [7], three stages of steatosis are 
defined. Stage I: enhanced echogenicity of the parenchyma 
with normal image of the vessels and the diaphragm boun­
daries. Stage II: higher number of minor and diffuse echoes 
in the parenchym a, poorer imaging of the vessels and 
the diaphragm boundaries. Stage III: significant num ber 
of diffuse echoes in the parenchyma and weak or absent 
imaging of the vessels, diaphragm and the distal part of the 
right lobe of the liver.
On experimantal examination of the toxic liver lesion in dogs, 
steatosis related changes on the US imaging (enlargement,
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higher echogenicity, lower echogenicity of the portal vein) 
are found as early as in the second day of the lesion. The 
most prominent changes were found between the days 2 
and 5 of the lesion. Furthermore, correlation between 
degree of changes in the sonographic images of the liver 
and histopathologic examination were found [8].
Relatively low sensitivity and specificity of the US are repor-
ted in diffuse lesions of the liver [9]. On the other hand,
sonography is sensitive in 89% and specific in 93% in diag nosis 
of the fatty liver, which was confirmed by histopathologic 
examination [10, 11]. Also on comparative CT and US imaging 
a close correlation between the high echogeni city and CT 
attenuation was demonstrated [12, 13]. 
Attempts of semiquantitative evaluation of steatosis degree 
in sonographic imaging are also made. Osawa at al. [14] 
evaluated US sensitivity at 91.3% based on histograms of 
semiquantitaive US images of the liver and the kidneys 
with different echogenicity ≥ 7 dB.
On sonographic Doppler imaging a negative correlation 
between steatosis and perfusion index is found as a propor-
tion of arterial flow to total liver flow [15]. Hamato et al. 
(16) found statistically significant changes in flow indices 
in the hepatic artery in patients with steatosis, chronic 
hepatitis and hepatic cirrhosis. Based on the Doppler 
imaging, steatosis and fibrosis changes in the liver were 
also significantly correlated with changes in flow parame-
ters in the hepatic veins [17].
CT imaging (CT)
CT attenuation (CTA) of the normal hepatic parenchyma 
at CT imaging with no contrast enhancement amounts 
to about 65±5 Hounsfield's units (HU) and is higher than 
attenuation of other visceral organs and muscles. Structures 
containing blood or bile (blood vessels and bile tracts) are 
visible as hypodense areas on non-enhanced background 
of the liver parenchyma. CT scan of the liver is usually 
performed in several phases. Scanning without contrast 
enhancement (CE) is combined with a repeated examination 
of the same area after i.v. contrast enhancement: in the 
arterial phase, the portal phase and occasionally in the 
late phase. The examination protocol containing a contrast 
enhance ment dosing, the rate of its administration and 
time delays are crucial for optimum quality images. The 
maxi mum enhancement of the aorta, hepatic artery and its 
branches is observed 12–17 s. after bolus CE (usually 3 ml/
kg body weight, using an automatic syringe) and imaging 
in the arterial phase should be performed at this delay. The 
consecutive scanning in the portal phase is performed at the 
delay of 40–60 s. after contrast enhancement. At this time 
range, the portal circulation vessels and the liver paren chy-
ma are visualised. Absorption of the contrasted paren chyma 
at the peak enhancement increases at about 20–25 HU in 
relation to examination without CE. Elimi nation of contrast 
media from the parenchyma is relatively quick and after 
5 mins 50% decrease in CT density is observed [18].
Hepatic accumulation of lipids results in a decrease of CT 
attenuation in the parenchyma without CE, because the 
adipose tissue has negative CT density values – from -70 HU 
to -100 HU. With a significant steatosis a contrast reversal 
can be observed, manifesting itself with hyperdense vessels 
on the hypodense parenchyma background. The main advan-
tage of CT imaging is a possibility of density mea sure ment 
at an optional area. The measurements are employed in 
semiquantitative evaluation of steatosis stages. A basis for this 
evaluation was developed in many experi men tal and clinical 
investigations in 1970s and 1980s. Kawata et al. [19] found 
significant correlations between triglycerides, cholesterol 
and cholesterol esters content and liver attenuation on CT 
examinations in the rats. Similar correlations were also 
found between histolo gically assessed steatosis stage and CT 
density of the liver. Ducommun et al. [20] found that 12–20 
HU decrease in CT density is associated with an accumulation 
of 20–40 mg lipids per 1 gram of the liver tissue.
The correlation between the hepatic lipid content and CT 
density of the liver was also confirmed in clinical studies. 
Yajima et al. [21] evaluated the liver attenuation in CT 
examinations in patients with different diffuse liver lesions. 
Figure 1.  Stage I liver steatosis in US examination; enhanced 
echogenicity of the liver parenchyma.
Rycina 1.  Stłuszczenie wątroby I stopnia w badaniu USG; zwiększona 
echogeniczność miąższu wątroby.
Figure 2.  Stage III liver steatosis in US examination; significant 
enhanced echogenicity and weak imaging of the vessels.
Rycina 2.  III stopień stłuszczenia wątroby w badaniu USG; znacznie 
zwiększona echogeniczność miąższu, słabe uwidocznienie 
naczyń wątrobowych.
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Both in the group of patients with cirrhosis and with 
chronic hepatitis, respectively, minor insignificant decrease 
in the CT density was noted. In patients with fatty liver, 
statistically significant decrease in CT attenuation below 50 
HU was found. Moreover, statistically significant correlation 
between the lipid content and CT density was noted. 
Assuming that steatosis occurs at the lipid content above 
100 mg/g fresh tissue, the authors suggest that a decrease of 
CT attenuation below 48 HU anables unequivocal diagnosis 
of the liver steatosis. Pamilo et al. [22] found that in mild 
steatosis (below 10%) CT density amounts to 39–60 HU, at 
the lipid content of 10–25% it decreases to 4–46 HU, and 
at the severe steatosis (above 25% lipid content) it may 
be negative (-6) - (+19) HU. The correlation between the 
histologically assessed steatosis grade and CT attenuation 
was also confirmed by Bydder et al. [23] in a group of 
patients with alcoholic fatty liver.
As the spleen displays a lower CT values (45±5 HU) in non-
enhancement CT scans compared with that of the liver, 
the assessment of the liver steatosis is also based on the 
liver/spleen index (L/S) expressed as the difference between 
the liver and the spleen attenuation (CTAL-CTAS) or their 
quotient (CTAL/CTAS). The liver/spleen index was found to 
correlate positively with the liver steatosis stage at the 
histo-morphometric examination [24]. Also, Ricci et al. 
[25] found there exists statistically significant correlations 
between CTA values of the liver, the L/S index and the lipid 
content based on the histo-morphometric examination in 
patients with the liver steatosis. Occasionally, the muscle 
tissue is used as the internal standard to compare the CTA 
values of the liver [26]. 
Additionally, attempts to develop a noninvasive method for 
the quantification of the hepatic fat content in vivo based 
on CT scans with the use of phantoms and callibration 
curves. Ricci et al. [25] found statistically significant cor-
relations between CTA values and terbutyl alcohol content 
in phantoms with different concentrations of the alcohol. 
CTA values of terbutyl alcohol used in the experiment are 
comparable to these of the adipose tissue. The authors 
found a close correlation between the liver lipid content in 
patients with the fatty liver based on callibrated CT scans 
and histomorphometric assessment. The authors emphasize 
the particular value of this method in patients with a mild 
steatosis. 
Contrast enhancement of the liver and the spleen is depen-
dent on the contrast medium dose, the rate of its admini-
stration and the scaning delay. Consequently, the enhanced 
CT scans are largely dependent on the examination protocol 
employed. Notwithstanding, qualitative and quantitative 
criteria of the liver steatosis diagnostics following the 
enhan ced CT scans were developed in clinical trials; 
however, CT attenuation values of the normal and fatty 
liver (and also the L/S index value) exhibit a slight overlap 
after enhancement [27]. Consequently, the enhanced CT 
scanning is not suggested as a diagnostic method in asses-
sment of steatosis, and the nonenhanced CT remains as a 
method of choice [28]. However, in order to obtain a better 
assessment of the liver parenchyma and the stage of its 
steatosis, attempts are being made to administer media 
that are specifically bound by hepatocytes. Bergman et al. 
[29] found in their experimental research on rats, that the 
liver steatosis is accompanied by a decrease accumulation 
of FP 736-04 emulsion that is specifically bound by hepato-
cytes. The authors also suggest that the analysis of the 
liver attenuation after FP 736-04 administration may be 
employed in the assessment of the liver steatosis.
Magnetic resonance imaging (MRI)
In MRI diagnostics of the fatty liver special sequences of 
fast gradient echo are used [30] combined with Chemical 
Shift Imaging (CSI) technique [31, 32, 33, 34]. Other methods 
of choice include gradient sequences „in-phase” and „in out-
phase” [35, 36] and magnetisation transfer imaging (MT). 
Alanen et al. [37] found out that the value of relative proton 
fat density in the latter method is significantly correlated 
with a proportion of steatosed hepatocytes in histologic 
examination.
Contrast media are uncommonly used in diagnostics of the 
liver steatosis. Contrast media of paramagnetics group 
(Gd-DTPA – gadopentetate dimeglumine) or suprapara-
magne tics group are used for diagnostics of steatosis-rela ted 
focal changes and differentiating from other types of focal 
changes [38]. Thus, the employment of organ-specific contrast 
media, e.g. Mn-DPDP (manganese-DPDP) or Gd-BOPTA/
dimeg (gadobenate dimeglumine) serves diag nostics and 
differentiating of focal changes in cases of fatty liver [39]. 
It is commonly accepted that liver steatosis is accopmanied 
by shortened time of lingitudinal relaxation (T1) due to 
triglyceride accumulation. However, results of relaxation 
time measurements T1 and T2 (transverse relaxation time) 
Figure 3.  Liver steatosis in CT; marked decrease of the liver CT 
attenuation compared to spleen and contrast reversal sign 
- hyperdense liver vessels on the hypodense parenchyma 
background.
Rycina 3.  Stłuszczenie wątroby w obrazie TK; znaczne obniżenie 
osłabiania wątroby w porównaniu ze śledzioną oraz obraz 
odwrócenia kontrastowego – hiperdensyjne naczynia 
wątrobowe widoczne na tle hipodensyjnego miąższu wątroby.
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are divergent in studies of different authors. Chai et al. [40] 
evaluated the relaxation times and magnetisation transfer 
phenomenon in two experimental models of fatty liver in rats. 
In cases of the acute steatosis the authors recorded increased 
relaxation times T1 and T2 and weaker effect of magnetisation 
transfer compared with the control group. Chronic liver 
steatosis was characterised by shortened values of T1 and T2 
and stronger effect of magnetisation transfer. Kreft et al. [39] 
found out that in simple liver steatosis in rats T1 is shortened 
by 15%, whereas steatosis with hepatocyte degeneration 
results in increase of T1 by 12%. On the other hand, T2 in both 
exparimental models correlated positively with the steatosis 
grade. The authors also found a significant correlation 
between a signal inten sity at conventional imaging in 
T1-weighted images, CSI images and the steatosis grade.
Other imaging methods
Single proton emission computed tomography (SPECT) and 
planar scintigraphy (PS) occasionally were used as diagnos-
tic methods in liver steatosia assessment. Delcourt et al. 
[41] demonstrated a high specificity of SPECT and planar 
scintigraphy in diagnostics of alcoholic liver steatosis. 
Antropometric indices in diagnostics of steatosis
Body mass index (BMI) may be used as a simple index indi-
cating a risk of liver steatosis. Rinella et al. [42] found no 
signs of liver steatosis in patients with BMI below 25. On 
the other hand, incodence of liver steatosis increased with 
BMI, from 33% at BMI of 25–28 to 76% at BMI above 28. 
The authors found a statistically significant correlation 
between BMI and incidence of the biopsy confirmed 
steatosis in a group of potential liver donors. 
However, all above-mentioned imaging techniques enable 
diagnosis of liver steatosis, assessment of lipid content and, 
consequently degree of the steatosis is qualitative rather 
than quantitative. Moreover, on CT and MRI exami nations a 
certain percentage of false negative results is noted. This is 
confirmed by by Rinella et al. [42] in their comparative studies 
in patients with MRI and CT diagno sed and subsequently 
biopsy confirmed fatty liver. However, in some cases of the 
biopsy-confirmed steatosis ima ging studies gave negative 
results: 24% and 30% pa tients diagno sed by CT and MRI, 
respectively. This is also confir med by observations by Ricci 
et al. [43] who found normal values of L/S index on CT scans 
in a significant proportion of patients with increased hepatic 
liver content based on histomorphometric assessment. 
1H MR spectroscopy in assessment of liver steatosis (1H MRS)
A high usefulness of 1H MR spectroscopy in assessment of 
lipid compounds content in the liver is confirmed by Szcze-
paniak et al. [44]. The authors in experimental investiga-
tions evaluated lipid content in the livers of dogs and rats 
and the influence of norepinephrine stimulation on changes 
of their levels. After norepinephrine administration, 
which enhances tissue lypolysis, a significant increase in 
hepatic liver content was found. The results indicated high 
Figure 4.  Fatty liver in MR examination. Hiperintense liver parenchyma 
in T2-weigthed axial image.
Rycina 4.  Stłuszczenie wątroby w badaniu MR. Hiperintensywny 
miąższ wątroby w obrazach T2-zależnych w płaszczyźnie 
poprzecznej.
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Figure 5.  1H MR spectra from healthy liver and patients with various 
stages of liver steatosis.
Rycina 5.  Widma spektroskopii 1H MR wątroby osoby zdrowej oraz 
chorych z różnymi stopniami stłuszczenia.
Figure 6.  1 H MR spectra from patients with chronic hepatitis with 
different inflammatory activity stage (G-grading) and fibrosis 
advancement (S-staging). 
Rycina 6.  Widma 1H MRS chorych z przewlekłym wirusowym zapaleniem 
wątroby z różnymi stopniami aktywności zapalnej (G-grading) 
oraz różnym zaawansowaniem włóknienia (S-staging).
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correlation between the lipid content evaluated by 1H MRS 
examination and biochemical and histological methods, both 
before and after norepinephrine administration. Also Choji 
at al. [45, 46] found correlations between lipid evaluation 
on 1H MRS examination and in vitro measurements in 
experimental model of liver steatosis in rats. 
Application of 1H MR spectroscopy to assessment of 
lipid compounds in the liver has been described in scarce 
reports, hitherto. Thomsen et al. [47] found correlation 
between hepatic lipid content using 1H MRS examination 
in vivo and biochemical methods, in the liver bioptates of 
patients with alcoholic liver steatosis at various stages. 
Longo et al. [24, 48] assessed grade of liver steatosis by 
comparing results of 1H MRS spectroscopy, CT scanning 
and histological examinations. The authors found 
significant correlation between ratio of lipid signal to 
sum of lipid and water signal in 1H MRS spectroscopy 
and value of L/S attenuation index in CT scanning. Both 
the lipid content assessed by MR spectroscopy as well as 
L/S index on CT scans was significantly correlated with 
the steatosis assessed histologically. Also Choji et al. 
[45] found a high correlation between lipid content on 
1H MRS and histological examinations in patients with 
fatty liver. According to the latter authors, sensitivity of 
1H MRS in diagnostics of fatty liver amounted to 100%, 
specificity to 83% at accuracy of 81% (in comparison with 
CT – respectively, 43%, 90% and 81%). Also in our own 
examinations a high usefulness of 1H MR spectroscopy in 
assessment of hepatic lipids content in healthy subjects 
and patients with diffuse parenchymal diseases was 
demonstrated [49, 50, 51].
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